This study aimed to characterize ␤ 3 -adrenergic receptors (ARs) in rat neonatal cardiomyocytes using the noradrenaline (NOR) properties to modulate the expression and function of the three ␤-ARs. We assessed the effect of NOR (physiological nonselective agonist), isoprenaline (ISO, ␤-nonselective agonist), dobutamine (DOB, ␤ 1 -selective agonist), and procaterol (PROC, ␤ 2 -selective agonist) on cAMP accumulation using cardiomyocytes untreated or treated with 100 M NOR for 24 h. The inhibition of forskolin-stimulated cAMP accumulation was determined using NOR, isoprenaline, and the 
and 1-(2-ethylphenoxy)-3-[[1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino-(2S)-2-propanol hydrochloride (SR 59230A) (␤ 3 -selective antagonist). In addition, the level of the three subtypes was determined by reverse transcription polymerase chain reaction and Western blotting. NOR pretreatment decreased the activation of cAMP induced by NOR, isoprenaline, and DOB, whereas PROC response was abolished. The inhibition of NOR response by CGP 20712A or ICI 118551 demonstrated that ␤ 1 -and ␤ 2 -ARs are down-regulated and that ␤ 2 -AR functional activity was also abolished in cardiomyocytes exposed to chronic stimulation. ␤ 3 -AR function was observed with NOR and ISO when ␤ 1 -/␤ 2 -ARs were blocked and with both ␤ 3 -selective agonists in NOR-treated cells only. This response was completely inhibited by SR 59230A and involved G i protein. Furthermore, the results from functional studies agree well with those from expression experiments. In conclusion, these data provide strong evidence that ␤ 3 -ARs are functionally upregulated and coupled to G i protein in rat neonatal cardiomyocytes following chronic exposure to NOR when ␤ 1 -and ␤ 2 -ARs are down-regulated.
Three ␤-adrenergic receptor subtypes (␤ 1 -, ␤ 2 -, and ␤ 3 -AR) have been cloned and pharmacologically characterized (Strosberg, 1995) . These different subtypes belong to the G protein-coupled receptor superfamily and modulate cardiac function after stimulation by the catecholamines, noradrenaline, and adrenaline. Increases in heart rate and force of contraction are mediated mainly by ␤ 1 -ARs and to a lesser extent by the ␤ 2 -AR (Dzimiri, 1999; Steinberg, 1999) . These functional effects result from the sequential activation of stimulatory G s proteins, adenylyl cyclase, and protein kinase A (PKA), leading to the phosphorylation of proteins involved in cardiac contractility (troponin I, L-type Ca 2ϩ channels, and phospholamban) (Post et al., 1999) . Previous studies have shown that the ␤ 2 -AR also couples to G i protein in cardiomyocytes (Xiao, 2001) . In contrast to ␤ 1 -and ␤ 2 -AR, activation of the ␤ 3 -AR induces a negative inotropic effect in different species, including human, dog, guinea pig, and rat (Gauthier et al., 1998 (Gauthier et al., , 1999 Kitamura et al., 2000; Cheng et al., 2001; Moniotte et al., 2001; Morimoto et al., 2004) . ␤ 3 -AR-mediated decrease in cardiac contractility involves coupling to G i/o protein(s) and activation of constitutively expressed endothelial nitric-oxide synthase and the subsequent generation of NO (Gauthier et al., 1998; Kitamura et al., 2000; Varghese et al., 2000; Brixius et al., 2004) . Furthermore, the functional activity of ionic currents such as L-type Ca 2ϩ and potassium I(Ks) are reduced by ␤ 3 -AR stimulation, which also modulates cardiac contractility (Kitamura et al., 2000; Cheng et al., 2001; Bosch et al., 2002; Morimoto et al., 2004) . Interestingly, ␤ 3 -AR expression level increases in failing myocardium in human (Moniotte et al., 2001 ) and dog (Cheng et al., 2001) , contributing to the depression of cardiac function (Morimoto et al., 2004) . In contrast, ␤ 1 -ARs are down-regulated, and both ␤ 1 -and ␤ 2 -ARs are uncoupled from G s proteins (Dzimiri, 1999) . It is widely accepted that heart failure induces an increase in the activity of the sympathetic nervous system, leading to an elevation in circulating catecholamines levels (Dzimiri, 1999; Steinberg, 1999) . We can assume that the consequences of elevated catecholamines are a decrease in the positive inotropic response to ␤ 1 -and ␤ 2 -ARs, and an increase in the negative inotropic activity induced by the ␤ 3 -AR, resulting probably in the impairment of the cardiac function as shown by Morimoto et al. (2004) . Furthermore, in adipocytes, chronic exposure to isoproterenol induces an increase in ␤ 3 -AR expression and a downregulation of ␤ 1 -AR level (Thomas et al., 1992) . The ␤ 1 -AR is also down-regulated in transgenic mice displaying cardiacspecific overexpression of the human ␤ 3 -AR (Kohout et al., 2001) . Similarly, in cardiomyocytes from ␤ 1 -and ␤ 2 -AR knockout mice, isoproterenol induced a small decrease in contraction rate involving presumably the ␤ 3 -AR (Devic et al., 2001) . In marked contrast, ␤ 1 -AR mRNA is up-regulated in white and brown adipose tissue isolated from ␤ 3 -AR knockout mice (Susulic et al., 1995) . Finally, Dinçer et al. (2001) showed that ␤ 1 -AR level decreases, whereas ␤ 3 -AR expression increases in hearts from diabetic rats, suggesting that the depressed cardiac function seen in chronic diabetes may be due to the modulation of ␤-AR subtype expression. Overall, these observations indicate that possible compensatory interactions exist between ␤ 1 -and ␤ 3 -AR expression and function. Therefore, in this study, we characterized the ␤ 3 -AR expression and function in neonatal cardiomyocytes using the properties of catecholamines to down-regulate ␤ 1 / ␤ 2 -ARs and presumably up-regulate ␤ 3 -ARs. We demonstrate for the first time that the ␤ 3 -AR subtype, which was not functional in neonatal cardiomyocytes under normal physiological conditions, is functionally up-regulated following chronic exposure to noradrenaline and inhibits cAMP accumulation through G i protein coupling. In marked contrast, ␤ 1 -and ␤ 2 -ARs were down-regulated.
Materials and Methods
Materials. Bovine serum albumin, Dulbecco's modified Eagle's medium (DMEM), fetal calf serum, fibronectin, forskolin, pertussis toxin, DL-norepinephrine hydrochloride, (Ϯ)-propranolol, hydrochloride, CL 316243 (CL), deoxynucleotide (dNTP) mix, IGEPAL CA-630, octylphenoxy polyethoxyethanol, and leupeptin were all obtained from Sigma Chemical (Poole, Dorset, UK). Trichloroacetic acid was purchased from Calbiochem (Nottingham, UK). Procaterol hydrochloride, xamoterol hemifumarate, isoproterenol hydrochloride, BRL 37344 (BRL), ICI 118551, CGP 20712A, and SR 59230A were all from Tocris Cookson Inc. (Bristol, UK). RQ1 RNase-free DNase, RNasin RNase inhibitor, dithiothreitol (molecular grade), random primers, Moloney murine leukemia virus reverse transcriptase, and TaqDNA polymerase were all purchased from Promega (Southampton, UK). ([8- 3 H]Adenine was obtained from GE Healthcare (Little Chalfont, Buckinghamshire, UK). Rat ␤ 1 -(sc-568), ␤ 2 -(sc-570), and ␤ 3 (sc-1473)-adrenergic receptor antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Cell Culture. Neonatal ventricular myocytes were prepared from 1-to 4-day-old Wistar rats using the neonatal cardiomyocyte isolation system (Worthington Biochemicals, Lornes Laboratories, Reading, UK) as described previously (Germack and Dickenson, 2004) . The cells were preplated three times for 30 min in a humidified incubator (95% air, 5% CO 2 at 37°C) in DMEM supplemented with 2 mM L-glutamine, 10% (v/v) fetal calf serum and penicillin/streptomycin (100 U/ml) to minimize fibroblast contamination. Cardiomyocyte-rich cultures (Ͼ90%) were plated onto fibronectin-coated plates at a final density of 1.25 ϫ 10 5 cells/cm 2 in supplemented DMEM. For cAMP accumulation assay, the cells were plated onto 24-well plates; and for RT-PCR and Western blotting, cells were plated onto 20-cm 2 dishes. After 3 days, confluent and spontaneously beating cells were serum starved overnight before the experiments and treated or not treated with 100 M noradrenaline.
cAMP Accumulation Assay. After serum starvation of cardiomyocytes (overnight), assays were carried out in serum-free DMEM in a humidified incubator (95% air, 5% CO 2 at 37°C). Agonists, antagonists, and/or inhibitors according to the experiments were added as described in the figure legends. The cells were incubated for 3 h in a humidified incubator (95% air, 5% CO 2 at 37°C) with 500 l of serum-free DMEM containing [ 3 H]adenine (2 Ci/well).
[ 3 H]adenine-labeled cells were washed twice with Hanks'/HEPES buffer and then incubated in 500 l/well serum-free DMEM containing the cyclic AMP phosphodiesterase inhibitor rolipram (10 M) for 15 min at 37°C in a humidified incubator. Agonists were added 5 min before the incubation with 1.5 M forskolin (10 min). Antagonist or inhibitors were added 30 min before agonist. Incubations were terminated by the addition of 500 l of 5% trichloroacetic acid after removing the medium. [
3 H]Cyclic AMP was isolated by sequential Dowex-alumina chromatography as described previously (Dickenson and Hill, 1998) . After elution, the levels of [ 3 H]cyclic AMP were determined by liquid scintillation counting.
RT-PCR. Total RNA was extracted from cardiomyocytes treated or not treated with 100 M noradrenaline using RNA isolation reagent, RNAwiz (Ambion, Eurotech, Huntingdon, UK). Total RNA was purified by chloroform/water extraction and isopropanol precipitation. All RNA preparations were treated with RQ1 DNase (1 U/l) for 20 min at 37°C in the presence of RNasin (40 U/l) and dithiothreitol (100 mM).
Reverse transcription was performed with 40 g of total RNA for the synthesis of cDNA using hexadeoxynucleotide random primers (540 ng/ml), RNasin (40 U/l), dNTP (5 mM), and Moloney murine leukemia virus reverse transcriptase (200 U/ml) for 90 min at 42°C. Polymerase chain reaction was conducted with 1 l of cDNA for ␤-actin, 3 l for ␤ 1 -and ␤ 2 -ARs, and 5 l for ␤ 3 -AR in the presence of dNTPS (1.25 mM), 200 ng of respective primers, and 1.5 U of TaqDNA polymerase. Following polymerase chain reaction, the samples were denatured for 5 min at 95°C. The amplification steps involved 1-min denaturation at 94°C for ␤ 1 -and ␤ 2 -AR cDNA and 1.5 min for ␤ 3 -AR and ␤-actin; 1 min annealing for ␤ 1 -, ␤ 2 -AR, and ␤-actin and 1.5 min for ␤ 3 -AR; and 1 min extension at 72°C for ␤ 1 -and ␤ 2 -AR and ␤-actin and 2 min for ␤ 3 -AR cDNA. Annealing temperatures, sequences of the primers and amplification cycle number are given in Table 1 . The RT-PCR products were analyzed using 1.5% agarose gel electrophoresis. ␤-Actin mRNA was used as an internal standard. The RT-PCR products were quantified by densitometry using GeneGenius BioImaging system (Syngene; Synoptics Ltd., Cambridge, UK) and normalized to the signal of ␤-actin. Western Blot Analysis. Cardiomyocytes treated or not treated with 100 M noradrenaline were washed with ice-cold phosphatebuffered saline and lysed in ice-cold hypotonic buffer (30 mM TrisHCl, 5 mM MgCl 2 , 100 mM NaCl, 1 mM EGTA, 0.1 mM phenylmethylsulfonyl fluoride, and 5 g/ml leupeptin). Cell membranes were collected by centrifugation for 30 min at 70,000g and 4°C. The resulting plasma membrane pellets were dissolved in detergent buffer [150 mM NaCl, 50 mM Tris-HCl, 5 mM EDTA, 1% (v/v) IGEPAL CA-630, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 1 mM Na 3 VO 4 , 1 mM NaF, 1 mM benzamidine, 0.1 mM phenylmethylsulfonyl fluoride, and 5 g/ml leupeptin]. Cell membrane homogenates were clarified by centrifugation (2 min; 12,000 rpm) using an Eppendorf microcentrifuge. Then, 100 l of the supernatant was removed and stored at Ϫ20°C until required. Protein concentration was determined using the Bio-Rad DC protein assay (Bio-Rad, Hertfordshire, UK) with bovine serum albumin as the standard. Samples were heated at 95°C in SDS-polyacrylamide gel electrophoresis sample buffer (v/v). Proteins (30 -40 g for ␤ 1 -, 40 -50 g for ␤ 2 -, and 60 -80 g for ␤ 3 -AR detection) were separated by SDS-polyacrylamide gel electrophoresis (12% acrylamide gel) using a Bio-Rad Mini-Protean II system (1 h at 200 V). Proteins were transferred to nitrocellulose membranes using a Bio-Rad Trans-Blot system (1 h at 100 V in 25 mM Tris, 192 mM glycine, and 20% MeOH). Following transfer, the membranes were washed with Tris-buffered saline (TBS) and blocked for 1 h at room temperature in blocking buffer [TBS, 5% (w/v) skimmed milk powder, and 0.1% Tween 20]. Blots were then incubated overnight at 4°C with ␤ 1 -, ␤ 2 -, or ␤ 3 -AR primary antibodies at the dilution 1/500, 1/100, and 1/50, respectively. The primary antibody was removed, and the blot was extensively washed three times for 5 min in TBS/Tween 20. Blots were then incubated for 1 h at room temperature with goat anti-rabbit and rabbit anti-goat secondary antibody coupled to horseradish peroxidase (DakoCytomation Ltd., Ely, Cambridgeshire, UK) at 1:1000 and 1/3000 dilution, respectively. Following removal of the secondary antibody, blots were extensively washed as described above and developed using the enhanced chemiluminescence detection system (GE Healthcare) and quantified by densitometry using GeneGenius BioImaging System (Syngene).
Statistical Analysis. Results are expressed as means Ϯ S.E. Concentration-response and inhibition-response curves were analyzed by computer-assisted iteration using Prism (GraphPad Software Inc., San Diego, CA). Statistical significance was determined by Student's t test, and P Ͻ 0.05 was considered as the limit of statistical significance.
Results
Effect of Nonselective, ␤ 1 -, and ␤ 2 -Selective Agonists on cAMP Accumulation in Neonatal Rat Cardiomyocytes Untreated or Treated with 100 M Noradrenaline. It is well known that chronic stimulation of ␤-ARs causes a decrease in ␤-adrenergic response by down-regulation of the ␤-ARs (Dzimiri, 1999; Steinberg, 1999) . Indeed, as shown in Fig. 1 and Table 2 , the response to noradrenaline (NOR; physiological ␣-and ␤-adrenergic agonist) and isoprenaline (ISO; nonselective ␤-adrenergic agonist) was significantly reduced by 61 and 77%, respectively, following the pretreatment with 100 M NOR for 24 h. The desensitization of the functional response depends mainly on the alteration of both, ␤ 1 -and ␤ 2 -ARs (Dzimiri, 1999; Steinberg, 1999) . Therefore, we determined the stimulation of cAMP induced by dobutamine (DOB; ␤ 1 -selective agonist) and procaterol (PROC; ␤ 2 -selective agonist) in untreated and treated cardiomyocytes ( Fig. 2 ; Table 2 ). Pretreatment with 100 M NOR resulted in a significant decrease in DOB-induced cAMP production by 81% without change in potency and abolished the PROC response ( Fig. 2B ; Table 2 ). The ␤ 2 -AR subtype is also coupled to PTX-sensitive G i proteins in addition to the classical G s /cAMP/PKA pathway (Xiao, 2001) . Therefore, ␤ 2 -AR-mediated G i activation can counteract G s -mediated cAMP production. This dual pathway may explain the low cAMP response to PROC stimulation in untreated cells and the absence of stimulation in treated cardiomyocytes. To determine whether the ␤ 2 -AR response involves G i coupling, cAMP accumulation was performed in the presence of PTX in treated and untreated cells. Pretreatment with PTX did not modify PROC-induced cAMP production ( Fig. 2B ; Table 2) , showing the absence of ␤ 2 -AR coupling to G i proteins in neonatal rat cardiomyocytes. In addition, these results indicate that the nonselective agonist response in NOR-treated cardiomyocytes involves the ␤ 1 -AR subtype rather than the ␤ 2 -AR. Effect of ␤ 1 -and ␤ 2 -Selective Antagonists on NORInduced cAMP Accumulation in Neonatal Rat Cardiomyocytes Untreated or Treated with 100 M Noradrenaline. To characterize further the ␤-AR subtypes involved in NOR-induced cAMP accumulation, we studied the inhibition of 1 M NOR response by the selective ␤ 1 -antagonist CGP 20712A and the ␤ 2 -antagonist ICI 118551 in cardiomyocytes untreated or treated with 100 M NOR (Fig.  3) . As expected, NOR pretreatment induced a decrease in 1 M NOR response by 72% (treated, 66 Ϯ 7% versus untreated, 239 Ϯ 11%; n ϭ 7; P Ͻ 0.001). As shown in the Fig.  3A , CGP 20712A inhibited by 58 Ϯ 4% NOR-induced cAMP accumulation in untreated cells. Following the pretreatment, NOR-induced cAMP response was fully inhibited (91 Ϯ 9% versus untreated; P Ͻ 0.01), indicating that the residual NOR response (42%) observed in untreated cells may involve ␤ 2 -AR stimulation. Pretreatment with 100 M NOR did not modify the CGP 20712A potency evaluated by its IC 50 expressed as Ϫlog 10 IC 50 (pIC 50 ), treated 7.83 Ϯ 0.15 (14.7 nM; n ϭ 3) versus untreated 7.72 Ϯ 0.21 (19.1 nM; n ϭ 3). Interestingly, ICI 118551 exhibited a significant biphasic inhibition curve in untreated cardiomyocytes (P Ͻ 0.01; Fig.  3B ). The first population of receptors with a high inhibition potency (pIC 50 ϭ 8.39 Ϯ 0.43; 4.1 nM; n ϭ 4) accounted for 32 Ϯ 7% of the total inhibition. The second part of the curve elicited 68 Ϯ 14% inhibition response with a pIC 50 value of 5.24 Ϯ 0.30 (5.8 M; n ϭ 4). Interestingly, the inhibition curve following NOR treatment was monophasic. The ICI 118551 potency was 5.63 Ϯ 0.30 (2.34 M; n ϭ 4) corresponding to the low-potency population with an inhibition response of 93 Ϯ 6% (P Ͻ 0.01 versus untreated), suggesting a complete down-regulation of the ␤ 2 -AR subtype in accordance with PROC-induced cAMP accumulation (Fig. 2B ). These data indicate that cAMP accumulation induced by NOR involved mainly ␤ 1 -AR subtype and weakly ␤ 2 -ARs, which is completely down-regulated following a chronic stimulation. Effect of Nonselective and ␤ 3 -Selective Agonists on Forskolin-Induced cAMP Accumulation in Neonatal Rat Cardiomyocytes Untreated or Treated with 100 M Noradrenaline. The ␤ 3 -AR coupled to G i/o protein is up-regulated in heart disease where NOR level is increased (Cheng et al., 2001; Moniotte et al., 2001 ) and in rat adipocytes following chronic agonist exposure (Thomas et al., 1992) . However, at present it is not known whether the ␤ 3 -AR is up-regulated in rat heart following agonist exposure. Therefore, we determined the effect of the nonselective agonists NOR and ISO and the selective ␤ 3 -AR agonists BRL and CL on forskolin-induced cAMP accumulation in untreated and treated neonatal rat cardiomyocytes with 100 M NOR for 24 h (Figs. 4, B and C, 5, 6, and 7) . We used 1.5 M forskolin to study ␤ 3 -AR stimulation. This concentration was under the maximal response of forskolininduced cAMP accumulation as illustrated in Fig. 4A . In untreated and treated cells, no significant inhibition was observed using both nonselective agonists. Indeed, NOR potentiated forskolin-induced cAMP accumulation (E max of 829 Ϯ 80% over the forskolin response; n ϭ 3) with a pEC 50 value of 7.23 Ϯ 0.18 (Fig. 4, B and C) . Pretreatment with 100 M NOR induced a significant decrease in the maximal response (E max of 115 Ϯ 38%; n ϭ 4; P Ͻ 0.001) without change in the potency (7.13 Ϯ 0.19). Similarly shown in Fig. 5 , ISO stimulated a marked increase in forskolin-induced cAMP accumulation (E max of 1883 Ϯ 293%; n ϭ 4), which was significantly down-regulated after treatment with NOR (E max of 257 Ϯ 56%; n ϭ 4; P Ͻ 0.01). The pretreatment did not modify the pEC 50 (treated cells, 7.23 Ϯ 0.40 versus untreated cells, 7.80 Ϯ 0.09). Interestingly, in the presence of 0.5 M propranolol (nonselective ␤-AR antagonist), a concentration that inhibits ␤ 1 /␤ 2 -AR responses (Strosberg, 1995; Germack et al., 1997) , NOR-induced an inhibition of forskolin-stimulated cAMP accumulation ( Fig. 4; Table 3 ). ISO also inhibited the forskolin-induced cAMP response in treated cardiomyocytes after incubation with 1 M CGP 20712A and ICI 118551, selective ␤ 1 -and ␤ 2 antagonists, respectively ( Fig. 5; Table 3 ). Since the percentage of inhibition with both nonselective agonists was similar, this would seem to exclude an effect of ␣ 1B -ARs in NOR-mediated inhibition of the forskolin response. This adrenergic subtype highly expressed in neonatal cardiomyocytes is negatively coupled to calcium channel via G i protein and therefore could inhibit adenylyl cyclase activity (Deng et al., 1996 (Deng et al., , 1998 . These data suggest that the functional expression of the ␤ 3 -AR in neonatal rat cardiomyocytes after treatment with 100 M NOR.
In untreated cells BRL potentiated forskolin-induced cAMP accumulation (645 Ϯ 34% over forskolin response; n ϭ 4) with a pEC 50 value of 6.03 Ϯ 0.07 (Fig. 6) . In contrast, the other selective ␤ 3 -AR agonist CL had no effect on forskolin-induced cAMP accumulation. Since the affinity of the ␤ 3 -AR for BRL in functional assays is around 1 nM (Germack et al., 1997 (Germack et al., , 2000 , the low potency would indicate the involvement ␤ 1 /␤ 2 -ARs. Following 24-h pretreatment with NOR, the effects of BRL on forskolin-stimulated cAMP accumulation were biphasic. At concentrations below 0.1 M, BRL inhibited forskolin-stimulated cAMP accumulation ( Fig. 6; Table 3 ). At concentrations above 0.1 M, BRL potentiated forskolin-stimulated cAMP accumulation by 17 Ϯ 1% with a potency of 6.47 Ϯ 0.99 (n ϭ 4). The potency was similar to the pEC 50 without treatment and the response was decreased by 97% (P Ͻ 0.001), suggesting a downregulation of ␤ 1 /␤ 2 -ARs. Finally, 0.5 M propranolol had no significant effect on BRL-mediated inhibition of forskolin cAMP accumulation ( Fig. 6; Table 3 ). However, propranolol inhibited BRL-induced cAMP responses in untreated cells, indicating ␤ 3 -Adrenergic Receptor in Cardiomyocytes strongly an activation of ␤ 1 /␤ 2 -ARs. Similarly, CL decreased forskolin-induced cAMP production in treated cells and 0.5 M propranolol did not change significantly the functional parameters ( Fig. 7 ; Table 3 ). Not only the functional expression of the ␤ 3 -AR subtype but also its coupling to G i were strengthened by using the selective ␤ 3 -AR antagonist SR 59230A (Fig. 8A ) and pertussis toxin (PTX; Fig. 8B ), respectively, which both abolished BRL-and CL-induced inhibition of forskolin response in NOR-treated cardiomyocytes. ␤ 1 -, ␤ 2 -, and ␤ 3 -AR mRNA and Protein Expression in Neonatal Rat Cardiomyocytes Untreated or Treated with 100 M Noradrenaline. To confirm the functional expression of the ␤ 3 -AR subtype in neonatal rat cardiomyocytes and its up-regulation after 24-h incubation with 100 M NOR, mRNA and protein expression of the three ␤-AR subtypes were examined by RT-PCR and Western blotting, (Figs. 9 and 10 ). Both ␤ 1 and ␤ 2 -AR mRNA (n ϭ 6) and protein expression (n ϭ 4) were significantly reduced, following NOR treatment, by around 40 and 55% of the control, respectively. The ␤ 2 -ARs seemed more sensitive to down-regulation than the ␤ 1 -AR, which may explain the absence of the ␤ 2 -AR response after treatment with NOR. In contrast, ␤ 3 -AR mRNA and protein levels increased by 156 and 169% of the control (n ϭ 5; P Ͻ 0.05) in treated cardiomyocytes, respectively. These data are in agreement with the functional studies showing a down-regulation of ␤ 1 /␤ 2 -AR response and an up-regulation of the ␤ 3 -AR following NOR treatment for 24 h.
Discussion
We show for the first time in this report that the ␤ 3 -AR subtype coupled to G i , is up-regulated and functional after chronic stimulation with noradrenaline when ␤ 1 -and ␤ 2 -ARs are down-regulated in neonatal rat cardiomyocytes. ␤ 1 -and ␤ 2 -ARs regulate cardiac function by increasing the rate and the force of contraction after stimulation by the catecholamines (noradrenaline and adrenaline) via G s /cAMP/ PKA signaling pathway (Dzimiri, 1999; Steinberg, 1999) . It is also well established that ␤ 1 -and ␤ 2 -ARs are down-regulated after a chronic stimulation. As expected, in this study, 24-h NOR pretreatment induced a decrease in NOR (physiological agonist) and ISO (␤-nonselective agonist) response by 61 and 77%, respectively ( Fig. 1; Table 2 ). In addition, cAMP production induced by the ␤ 1 -selective agonist (dobutamine) was decreased by 81% in treated cardiomyocytes, whereas the ␤ 2 response using procaterol was abolished ( Fig. 2; Table 2 ). The inhibition study using CGP 20712A (␤ 1 -selective antagonist) and ICI 118551 (␤ 2 -selective antagonist) (Fig. 3) supports the findings obtained in agonist-induced cAMP response. Indeed, 1 M NOR-induced cAMP accumulation was partially blocked by CGP 20712A in untreated cardiomyocytes, whereas NOR response was abolished following 24-h exposure to NOR without change in pIC 50 , indicating the same population of receptors. Interestingly, the biphasic inhibition of NOR response by ICI 118551 indicated the presence of a minor population of receptors (32 Ϯ 7% of inhibition) with high potency in untreated cells, which disappeared following NOR pretreatment. These data indicate that not only ␤ 2 -AR is more sensitive to down-regulation than ␤ 1 -ARs but also ␤ 2 -AR subtype represents the minor population of ␤-ARs in normal physiological conditions in neonatal cardiomyocytes. This last finding is in agreement with the dose-response curves using ␤ 1 -and ␤ 2 -selective agonists previously discussed. Indeed, the maximal response induced by the ␤ 2 - Fig. 9 . Expression of ␤ 1 -, ␤ 2 -, and ␤ 3 -AR mRNA obtained from untreated (control) and treated with 100 M noradrenaline for 24 h neonatal rat cardiomyocytes. Total RNA was prepared and semiquantitative RT-PCR was carried out as described under Materials and Methods. Values were obtained by densitometric analysis of RT-PCR products and normalized to ␤-actin signal. Data (top) are expressed as the percentage of untreated cardiomyocytes (100%). The bottom displays 2% agarose gel electrophoresis of ␤ 1 -, ␤ 2 -, and ␤ 3 -ARs and ␤-actin; line 1, line 2, line 3, and line 4 correspond to the ladder, untreated control cells, treated cells, and primer control without cDNA, respectively. Each point represents the mean Ϯ S.E. of five to six independent experiments. ‫,ء‬ P Ͻ 0.05 and ‫,ءءء‬ P Ͻ 0.001 versus untreated control.
␤ 3 -Adrenergic Receptor in Cardiomyocytes 399 selective agonist was lower by 57% than ␤ 1 -AR maximal stimulation in untreated cells, indicating clearly that the ␤ 1 -ARs are mainly expressed in neonatal cardiomyocytes in normal physiological conditions as already shown in heart from different species (Steinberg, 1999) . Likewise, the expression of ␤ 1 -and ␤ 2 -ARs evaluated by RT-PCR and Western blotting (Figs. 9 and 10) revealed that ␤ 1 -ARs are highly expressed and resistant to a chronic NOR stimulation compared with ␤ 2 -ARs. Susuki et al. (1992) have shown that ␤ 1 -and ␤ 2 -ARs expressed in Chinese hamster fibroblast at the same expression level were also differently regulated following 24-h pretreatment with isoprenaline. ␤ 2 -ARs are also coupled to PTX-sensitive G i protein in addition to the classical G s /cAMP/PKA pathway in adult rat and mouse cardiomyocytes (Xiao et al., 1995 (Xiao et al., , 1999 and human atrium (Kilts et al., 2000) . However, in the present study, PTX pretreatment did not modify procaterol response in untreated or treated cells, suggesting that ␤ 2 -ARs are not coupled to PTX-sensitive G i protein in neonatal rat cardiomyocytes as already shown in these cells (Vitalyi et al., 2003) . Overall, these results demonstrate that ␤ 1 -and ␤ 2 -ARs are involved in G s /cAMP/PKA signaling pathway and differentially downregulated in neonatal cardiomyocytes.
In contrast to ␤ 1 -and ␤ 2 -ARs, the ␤ 3 -AR induces a decrease in cardiac contractility in different species, including human, dog, guinea pig, and rat (Gauthier et al., 1999; Kitamura et al., 2000; Cheng et al., 2001; Morimoto et al., 2004) . A coupling of ␤ 3 -ARs to G i/o protein and the activation of endothelial nitric-oxide synthase mediate this negative inotropic effect (Gauthier et al., 1998; Kitamura et al., 2000; Varghese et al., 2000; Brixius et al., 2004) . Therefore, the modulation of cardiac contractility by the ␤ 3 -ARs seems to involve the inhibition of the adenylyl cyclase and the decreased in intracellular cAMP content. In contrast, this subtype controls lipolysis in rat white adipocytes (Van Liefde et al., 1992; Germack et al., 1997) and thermogenesis in brown adipocytes (Atgie et al., 1997) through G s protein activation. However, a dual coupling of the ␤ 3 -ARs to G s and G i has been reported in white adipocytes (Chaudhry et al., 1994) and 3T3-F442A adipocytes (Soeder et al., 1999) . ␤ 3 -ARs are also expressed in gastrointestinal smooth muscles and mediate relaxation through G s protein and cAMP-independent mechanism (Horinouchi et al., 2003) . To determine the physiological significance of ␤ 3 -ARs, we determine the effect of NOR on forskolin-induced cAMP accumulation ( Fig. 4; Table 3 ). NOR produced an inhibition of forskolin response in NOR-treated cardiomyocytes only when propranolol was added and used at the concentration, which inhibits ␤ 1 -and ␤ 2 -ARs. Similarly, forskolin-mediated cAMP accumulation was inhibited by ISO in the presence of the selective ␤ 1 -and ␤ 2 -antagonists following a chronic stimulation with NOR ( Fig. 5; Table 3 ). Gauthier et al. (1998) have also reported that NOR induced a negative inotropic effect when ␣-and ␤ 1 /␤ 2 -ARs were inhibited in human heart. Similarly, ␤ 3 -AR decreased potassium channel activity in the presence of ␤ 1 -and ␤ 2 -antagonists in guinea pig cardiomyocytes (Bosch et al., 2002) . These observations indicate that ␤ 3 -ARs are not involved in the regulation of the cardiac function in normal physiological conditions (neonatal cardiomyocytes; this study) or that this subtype plays a minor role in the modulation of the functional response (human and guinea pig). NOR and ISO pIC 50 values were in the same range as the corresponding potencies for cAMP accumulation observed in rodent ␤ 3 -ARs expressed in Chinese hamster ovary cells (Strosberg, 1997) , suggesting the expression of ␤ 3 -ARs in neonatal cardiomyocytes when ␤-ARs are continuously activated. The inhibition of forskolin response by BRL and CL, both ␤ 3 -selective agonists, was in the similar range in cardiomyocytes treated with NOR in absence or presence of propranolol to prevent ␤ 1 -and ␤ 2 -ARs effect (Figs. 6 and 7; Table 3 ). Moreover, BRL potentiated forskolin response with a low activity in untreated cardiomyocytes contrary to CL, which had no effect. Furthermore, following NOR pretreatment, BRL dose-response curve was biphasic and displayed a down-regulation of the low-potency component, indicating that this agonist lacks selectivity at concentrations Ͼ100 nM and stimulates ␤ 1 -and ␤ 2 -ARs. In addition, in this study, the potency order of BRL Ͼ ISO Ͼ NOR in NOR-treated cells was characteristic of the ␤ 3 -AR subtype as reported previously (Strosberg, 1997; Atgie et al., 1997; Germack et al., 1997; Horinouchi et al., 2003) . Interestingly, CL is more potent in adipocytes than in human heart to stimulate ␤ 3 -ARs (Atgie et al., 1997; Umekawa et al., 1997 Umekawa et al., , 1999 Gauthier et al., 1999) as we also found in neonatal cardiomyocytes. Rodent ␤ 3 -AR gene contains two introns, which by alternate splicing can generate two variants, which differ at the C-terminal region (Strosberg, 1997) . The different expression of one of both isoforms can explain the pharmacological difference between adipocytes and cardiomyocytes. The inhibition of forskolin by BRL and CL was abolished using the ␤ 3 selective antagonist SR 59230A (Fig.  8 ) in NOR-treated cells. Furthermore, PTX treatment also counteracted completely both agonist responses (Fig. 8) , indicating clearly the involvement of G i protein in ␤ 3 -AR transduction pathway in neonatal rat cardiomyocytes as shown in human, dog, and guinea pig heart (Gauthier et al., 1999; Kitamura et al., 2000; Cheng et al., 2001; Morimoto et al., 2004) . Results from functional studies agree well with those from RT-PCR and Western blotting (Figs. 9 and 10) , showing an up-regulation of the ␤ 3 -AR subtype following NOR pretreatment. Overall, these data provide strong evidence that ␤ 3 -ARs are functionally expressed after being up-regulated following a chronic stimulation in neonatal cardiomyocytes. Similarly, Thomas et al. (1992) demonstrated that adipocytes continuously stimulated with isoprenaline display an enhancement in ␤ 3 -AR level and a reduction of ␤ 1 -AR subtype. Although no ␤ 3 -AR functional response was observed in untreated neonatal cardiomyocytes, the present data may partially explain the up-regulation of ␤ 3 -ARs described in failing myocardium (Cheng et al., 2001; Moniotte et al., 2001 ), especially as circulating catecholamines are elevated in heart failure (Dzimiri, 1999; Steinberg, 1999) . Morimoto et al. (2004) demonstrated that the functional up-regulation of the ␤ 3 -ARs contributes to the depression of the cardiac function in cardiomyocytes from dog with pacing-induced cardiac heart failure. Therefore, the regulation of cardiac contractility by catecholamines in heart disease indicate an opposite compensatory modifications between ␤ 1 /␤ 2 -and ␤ 3 -ARs. Kohout et al. (2001) have reported that ␤ 1 -AR expression was lower in transgenic mice displaying cardiac specific overexpression of the human ␤ 3 -AR. In contrast, ␤ 3 -AR knockout mice exhibited an increase in ␤ 1 -AR mRNA in white and brown adipose tissue (Susulic et al., 1995) . Finally, ␤ 1 -AR subtype decreases and ␤ 3 -AR level increases in hearts from diabetic rats explaining partially the impairment in cardiac function in chronic diabetes (Dinçer et al., 2001 ).
In conclusion, we demonstrate for the first time that the ␤ 3 -AR subtype, which was not functional in neonatal rat cardiomyocytes under normal physiological conditions, was functionally up-regulated following chronic exposure to noradrenaline and inhibited cAMP accumulation through G i protein coupling, whereas, ␤ 1 -and ␤ 2 -ARs were down-regulated. The rank order of functional expression of ␤-ARs is ␤ 1 Ͼ ␤ 2 in physiology conditions and ␤ 1 Ͼ ␤ 3 in chronic ␤-AR stimulation. Neonatal rat cardiomyocytes represent a suitable in vitro model to study further the role of ␤ 3 -AR subtype in heart disease.
